Key result
Cardiometabolic prevention requires shifting to lifelong, multidisciplinary care targeting cumulative ApoB exposure.
Why the study?
Despite advances in understanding and treatment, cardiometabolic diseases remain leading causes of premature mortality and healthcare burden due to an evidence-to-practice gap in prevention.
Answers are grounded in this paper and cite their sources.
This narrative review highlights that closing the evidence-to-practice gap in cardiometabolic prevention requires transitioning from episodic risk factor management to lifelong, multidisciplinary care pathways focused on cumulative ApoB exposure, implementation science, and treatment adherence.
Cardiometabolic diseases—principally cardiovascular disease, type 2 diabetes, and obesity—remain leading global drivers of premature mortality, disability, and healthcare expenditure, despite substantial advances in their biological understanding, risk assessment, and treatment. This narrative review critically examines why increasingly effective preventive interventions have failed to yield a commensurate reduction in population-level disease burden, identifying the biological, clinical, organizational, economic, and social factors that sustain this evidence-to-practice gap. It integrates evidence across three complementary dimensions: (1) The biological continuum, linking metabolic dysfunction, chronic low-grade inflammation, and cumulative exposure to apolipoprotein B (ApoB)-containing lipoproteins with atherosclerotic cardiovascular disease; (2) The clinical continuum, extending from early risk recognition and targeted diagnostic evaluation to individualized intervention and longitudinal reassessment; and (3) The organizational continuum, required to deliver coordinated, multidisciplinary prevention across health systems. Particular attention is given to total and lifetime cardiovascular risk, the clinical application and limitations of SCORE2 and SCORE2-OP, and the diagnostic challenges of identifying younger or apparently healthy individuals whose low short-term risk masks significant cumulative lifetime exposure. The review critically evaluates the causal role and clinical interpretation of ApoB-containing lipoproteins, including lipoprotein(a) [Lp(a)], and the complementary role of emerging biomarkers and subclinical atherosclerosis imaging, while carefully distinguishing enhanced risk prediction from demonstrated improvements in hard clinical outcomes. An educational and translational clinical vignette illustrates how the longitudinal interpretation of routine clinical and laboratory data supports proportionate assessment of persistent dyslipidemia, treatment response, and plausible primary and secondary contributors to cardiometabolic risk well before symptom onset. Rather than attributing borderline abnormalities to a single occult disorder, the vignette demonstrates how standardized confirmation, verification of medication exposure, etiological assessment, targeted referral, and structured reassessment can translate routine data into actionable preventive pathways. Ultimately, this analysis indicates that cardiometabolic prevention is constrained less by a lack of scientific evidence or effective pharmacotherapies than by delayed risk recognition, therapeutic inertia, poor treatment adherence, fragmented care pathways, limited multidisciplinary coordination, structural health inequalities, and the incomplete integration of clinical, laboratory, behavioral, environmental, and patient-reported data. Improving outcomes therefore demands a systemic shift from episodic, disease-specific management toward early, lifelong, proportionate, coordinated, equitable, and patient-centered cardiometabolic prevention—underpinned by implementation science, precision prevention, digital health solutions, health-economic evaluations, patient-reported outcome measures (PROMs), and patient-reported experience measures (PREMs).
No takes yet. Share an insight, caveat, or question.
Krzyściak et al. (2026) conducted a review in Cardiometabolic diseases (cardiovascular disease, type 2 diabetes, and obesity) and atherosclerotic cardiovascular disease risk. Lifelong, coordinated, system-wide cardiometabolic prevention (including SCORE2/SCORE2-OP risk stratification, ApoB and Lp(a) evaluation, lifestyle modification, and early combination lipid-lowering pharmacotherapy) vs. Episodic, disease-specific management was evaluated on Population-level cardiometabolic disease burden and major adverse cardiovascular events. Cardiometabolic prevention requires a systemic shift from episodic care to lifelong, coordinated, multidisciplinary pathways addressing cumulative ApoB exposure and implementation barriers.
Synapse has enriched 10 related papers. Consider them for comparative context: